Portfolio Companies

The goal of CRV is to unlock the potential of UNC-Chapel Hill technologies and advance the commercialization of these technologies by providing early-stage capital and industry expertise. Beginning in 2016, CRV expects to make three to four investments per year.

Direct Investments

Inhalon Biopharma
Falcon Therapeutics

L2 Ventures I

NoviSci
WalletFi
Bivarus
410 Medical
StrideBio
Ribometrix
Genturi
G1 Therapeutics

L2 Ventures II

Altis Biosystems
IMMvention Therapeutix